AI assistant
Q-Linea — Share Issue/Capital Change 2023
Aug 2, 2023
3100_rns_2023-08-02_dbe1cd78-aa4a-4015-bbb5-e62f43b246c4.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Change in the number of shares and votes in Q-linea AB
Q-linea AB (publ) ("Q-linea" or the "Company") (Nasdaq Stockholm: QLINEA) announces that the number of shares and votes in Q-linea has increased due to the underwritten rights issue of shares. The press release regarding the issue of shares was published on 1 June 2021. A total of 87,628,425 ordinary shares and votes have been added.
At 31 July 2023 the number of shares and votes in the Company amounts to 117,166,372. All shares are ordinary shares.
For further information, please contact:
Christer Samuelsson, CFO / IR, Q-linea AB [email protected] + 46 (0) 70-600 15 20
About Q-linea
Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.
This information is information that Q-linea is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-08-02 08:30 CEST.